“There is a lot of anticipation” for the results that will emerge from the ongoing tests on the personalized mRNA vaccine against melanoma, i.e. tailor-made…
Already a subscriber? Log in here!
SPECIAL OFFER
FLASH OFFER
ANNUAL
€49.99
€19
For 1 year
CHOOSE NOW
MONTHLY
€4.99
€1 PER MONTH
For 3 months
CHOOSE NOW
SPECIAL OFFER
SPECIAL OFFER
MONTHLY
€4.99
€1 PER MONTH
For 3 months
CHOOSE NOW
Then only €49.99 instead of €79.99/year
Subscribe with Google
“There is a lot of anticipation” for the results that will emerge from the ongoing tests on the vaccine mRna personalized against melanoma, i.e. tailor-made for the individual patient’s tumor. Also the United Kingdom is treating its first patients.
«The news reported in the UK» tells «of the process of a phase 3 study which is now starting in the various countries. We in Italy started in December 2023, the study is progressing. In our country there are 5 centers involved, enrollment is progressing and going very well. Many patients are participating and therefore we hope to have the results within 3 years.” This was presented to Adnkronos Salute by the oncologist of the National Cancer Institute Irccs Fondazione Pascale of Naples, Paolo Asciertodirector of the Department that deals with skin tumors, experimental cancer immunotherapy and innovative therapies.
«The timetable is respected – the expert points out – and the enrollment can probably be closed even earlier. The process will be further speeded up now with the addition of the United Kingdom, because then we will have more patients and this certainly means greater speed” in data collection. «In Italy I believe around fifty patients have already been enrolled, we are ahead and there are many others who are being screened, waiting to see if they can enter the study. Our country’s performance is important” on this front. Going into the merits of the vaccine, “this further innovation is expected” in the world of oncology, reasons the specialist.
«The data from the phase 2 study are very promising and therefore there is a lot of anticipation. And if the study were to be positive, on the one hand it changes the standard of adjuvant treatment” for melanoma, “but it also opens the door to further trials for other types of tumors. There are already some underway, which are also important. So we’ll see. Personalizing the activity of the immune system is certainly a very interesting approach.”
© ALL RIGHTS RESERVED
Read the full article at
The morning
